Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 1:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 7,054 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Tumors Clear all
Terminated Phase 2 Interventional Results available

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

NCT05169437
View directory record Official record
Conditions
Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer
Interventions
Niraparib
Drug
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
80
States / cities
Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 1, 2026, 1:56 PM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Use of Supine MRI Images in Breast Conserving Surgery

NCT01929395
View directory record Official record
Conditions
Breast Cancer
Interventions
Supine MRI
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 1, 2026, 1:56 PM EDT
Terminated No phase listed Observational

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

NCT01232881
View directory record Official record
Conditions
Breast Cancer
Interventions
Tumor Sample, Serum Sample
Procedure
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 1, 2026, 1:56 PM EDT
Completed Not applicable Interventional

Rural Women Connecting for Better Health

NCT01441011
View directory record Official record
Conditions
Breast Cancer, Obesity
Interventions
Group phone counseling, Newsletter
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Up to 75 Years · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 1, 2026, 1:56 PM EDT
Not listed Not applicable Interventional

Immune Effects in Patients Treated With Whole Breast Irradiation

NCT03567044
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood Draw
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
45 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 1, 2026, 1:56 PM EDT
Not yet recruiting Phase 2 Interventional

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

NCT07619365
View directory record Official record
Conditions
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Lovastatin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 1, 2026, 1:56 PM EDT
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

NCT01966471
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab Emtansine, Trastuzumab, Pertuzumab, Paclitaxel, Epirubicin, Doxorubicin, Docetaxel, Cyclophosphamide, 5-Fluorouracil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
50
States / cities
Scottsdale, Arizona • Oakland, California • Roseville, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 1, 2026, 1:56 PM EDT
Completed No phase listed Observational

Tracking Physical Activity Throughout Chemotherapy for Breast Cancer

NCT03041545
View directory record Official record
Conditions
Breast Cancer, Physical Activity
Interventions
Fitbit
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 85 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 1, 2026, 1:56 PM EDT
Completed Not applicable Interventional Results available

Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study

NCT03624972
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Starting the Conversation Video, Sexual and Menopausal Health Resources
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 1, 2026, 1:56 PM EDT
Completed No phase listed Observational

Patient Preferences for Breast Reconstruction After Mastectomy

NCT01488357
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 1, 2026, 1:56 PM EDT
Completed Not applicable Interventional Results available

Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography

NCT02306265
View directory record Official record
Conditions
Breast Cancer, Tumors, Breast, Cancer Screening
Interventions
FFDM, DBT
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
30 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Royal Oak, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 1, 2026, 1:56 PM EDT
Recruiting Phase 3 Interventional

Two Versus One Week Breast Radiotherapy (RT)

NCT06960707
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation therapy - 1 week, Radiation therapy - 2 weeks
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 1, 2026, 1:56 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

NCT05941507
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
LCB84, Anti-PD-1 monoclonal antibody
Drug
Lead sponsor
LigaChem Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 1, 2026, 1:56 PM EDT
Completed Not applicable Interventional

Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer

NCT04493034
View directory record Official record
Conditions
Breast Cancer
Interventions
Art Therapy, Music Therapy
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 1, 2026, 1:56 PM EDT
Not listed Phase 1 Interventional

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

NCT03129139
View directory record Official record
Conditions
Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Interventions
Minnelide™Capsules
Drug
Lead sponsor
Minneamrita Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 1, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Results available

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

NCT02586675
View directory record Official record
Conditions
Breast Cancer, Breast Cancer - Female, Breast Cancer - Male
Interventions
Tamoxifen, Ribociclib, Goserelin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 1, 2026, 1:56 PM EDT
Completed Phase 2 Interventional Results available

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

NCT01091428
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma
Interventions
Alisertib, Paclitaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
The Bronx, New York • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 1, 2026, 1:56 PM EDT
Recruiting Not applicable Interventional

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

NCT03723928
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Interventions
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
709
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 1, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multi-modality Imaging Assessment of Chemobrain

NCT00708045
View directory record Official record
Conditions
Cancer
Interventions
[18F]fluoro-2-deoxy-D-glucose (FDG)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 1, 2026, 1:56 PM EDT
Completed Not applicable Interventional Results available

Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy

NCT03061175
View directory record Official record
Conditions
Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Internet-Based Intervention, Survey Administration
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Charlestown, Massachusetts • New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 1, 2026, 1:56 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Efficacy of Acupuncture for Hot Flashes in Women Treated With Hormonal Therapy for Breast Cancer

NCT00209001
View directory record Official record
Conditions
Breast Cancer
Interventions
Acupuncture, Sham acupuncture therapy
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 1, 2026, 1:56 PM EDT
Completed Phase 2 Interventional

A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.

NCT00078000
View directory record Official record
Conditions
Breast Neoplasms
Interventions
SU011248
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
Greenbrae, California • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2008 · Synced Oct 1, 2026, 1:56 PM EDT
Not listed Phase 1 Interventional

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

NCT02637531
View directory record Official record
Conditions
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
Interventions
IPI-549 (eganelisib), Nivolumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
11
States / cities
San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 1, 2026, 1:56 PM EDT
Recruiting Phase 2 Interventional

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT07112053
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, F-18 16 Alpha-Fluoroestradiol, Hormone Therapy, Positron Emission Tomography, Biopsy Procedure, Biospecimen Collection, Abemaciclib
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 1, 2026, 1:56 PM EDT